(Q41180671)

English

Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I.

scientific article published on April 1991

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. The American Exosurf Neonatal Study Group I. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

child mortality

0 references

bronchopulmonary dysplasia

1 reference

based on heuristic

inferred from title

author name string

Long W

1

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Thompson T

2

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Sundell H

3

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Schumacher R

4

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Volberg F

5

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Guthrie R

6

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

language of work or name

0 references

publication date

1 April 1991

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

The Journal of Pediatrics

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

4 Pt 1

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

595-605

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Prophylactic treatment of very premature infants with human surfactant

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Ten centre trial of artificial surfactant (artificial lung expanding compound) in very premature babies. Ten Centre Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. American Exosurf Pediatric Study Group 1

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomized prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Effects of a protein-free, synthetic surfactant on survival and pulmonary function in preterm lambs

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Lung function in prematurely delivered rabbits treated with a synthetic surfactant

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Pulsating bubble technique for evaluating pulmonary surfactant

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

A captive bubble method reproduces the in situ behavior of lung surfactant monolayers

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Artificial surfactant treatment in lambs with severe respiratory distress syndrome: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Artificial surfactant therapy in hyaline-membrane disease

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Increased shunt through the patent ductus arteriosus after surfactant replacement therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Medical management of small preterm infants with symptomatic patient ductus arteriosus

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Hemodynamically significant PDA: an echocardiographic and clinical assessment of incidence, natural history, and outcome in very low birth weight infants maintained in negative fluid balance

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Bronchopulmonary dysplasia: the pulmonary pathologic sequel of necrotizing bronchiolitis and pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

A European multicenter randomized controlled trial of single dose surfactant therapy for idiopathic respiratory distress syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2805%2983388-8

7 January 2021

Identifiers

10.1016/S0022-3476(05)83388-8

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41180671&oldid=1526067081"